Latest News

A new study presented at the National Society of Genetic Counselors Annual Conference highlights strong interest among individuals at risk for Huntington disease in undergoing modifier gene testing, underscoring the growing role of genetic insights in personal and clinical decision-making.

Axsome Therapeutics advances AXS-05 for Alzheimer agitation, showcasing promising trial results and potential for treating major depressive disorder.

A new study presented at NSGC 2025 showed that patients living with amyotrophic lateral sclerosis considering medical aid in dying often experienced emotional and logistical challenges with the process.

A recent study highlights the link between genetic neurodevelopmental disorders and increased gastrointestinal issues in pediatric patients, emphasizing the need for targeted care.

A new study reveals that early treatment with the Nerivio wearable significantly enhances migraine relief, doubling efficacy outcomes for patients.

Brad Racette, MD, FAAN, the Kemper and Ethel Marley Chair for Neurology at Barrow Neurological Institute, discussed his keynote lecture on the neurologic health effects of electric vehicles and the global implications of environmental exposure.

Spinogenics presents promising data on SPG302, a daily tablet showing cognitive improvements in Alzheimer's patients with excellent safety profiles.

A 2025 study published in Neurology® found that people with both gum disease and dental cavities face significantly higher long-term risks of stroke and major cardiovascular events compared with those with good oral health.

Feedback from the FDA allows CervoMed to move forward with the proposed primary and secondary end point of the phase 3 trial assessing neflamapimod in dementia with Lewy bodies.

New clinical trial results show LT3001's promise in treating acute ischemic stroke, demonstrating safety and improved patient outcomes without complications.

The associate professor of physical medicine and rehabilitation at Virginia Commonwealth University discussed his passion for educating others about electrodiagnosis and ultrasound in neuromuscular disorders.

A physician assistant who specializes in neurology previewed her upcoming presentation on evaluating patients with headache at the 2025 Baptist Miami Neuroscience Symposium.

A phase 3 study evaluates remibrutinib's safety and efficacy for generalized myasthenia gravis, promising new treatment options for patients.